Table. 1.

Baseline recipient characteristics

Variable TAC (n=95) EVR-TAC (n=36) P-value
Male sex 59 (62.1) 22 (61.1) 0.917
Age (yr) 53 (28–77) 51 (20–68) 0.453
Body mass index (kg/m2) 24.9 (14.9–38.0) 23.0 (17.5–37.9) 0.014
Hypertension 15 (15.8) 6 (16.7) 0.932
Diabetes 24 (25.3) 5 (13.9) 0.238
Diagnosis 0.713
Alcoholic 32 (33.7) 8 (22.2)
Hepatitis B virus 41 (43.2) 14 (38.9)
Hepatitis C virus 4 (4.2) 4 (11.1)
Non B, non C 8 (8.4) 5 (13.9)
Autoimmune 3 (3.2) 1 (2.8)
Toxic 3 (3.2) 2 (5.6)
Hepatitis A virus 2 (2.1) 1 (2.8)
Others 2 (2.1) 1 (2.8)
Coexistence of HCC 25 (26.3) 8 (22.2) 0.822
MELD 33 (7–40) 37 (13–40) 0.135
Child-Pugh class 0.129
A 5 (5.3) 0
B 21 (22.1) 6 (16.7)
C 69 (72.6) 30 (83.3)
CKD pretransplant 8 (8.4) 9 (25.0) 0.019
eGFR pretransplant (mL/1.73 m2) 67.4 (6.4–123.7) 54.2 (5.9–114.4) 0.054
Cr pretransplant (mg/dL) 1.05 (0.31–3.08) 1.24 (0.44–3.80) 0.086

Values are presented as number (%) or median (range).

TAC, tacrolimus treatment group; EVR-TAC, combination of everolimus and reduced tacrolimus treatment group; HCC, hepatocellular carcinoma; MELD, model for end-stage liver disease; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; Cr, creatinine.

Korean J Transplant 2021;35:8~14 https://doi.org/10.4285/kjt.20.0043
© Korean Journal of Transplantation